

Industry update

With so many ongoing advances in the management of diabetes, this section keeps you up to date with product-related developments and other relevant news

OneTouch Verio®IQ System launched

LifeScan has launched the OneTouch® Verio®IQ system, which is designed to identify patterns of high or low blood glucose, enabling patients and healthcare professionals to take early corrective action, and potentially helping reduce diabetes-associated complications. The strip features Verio® PatternAlert™ technology, which alerts patients to only the most relevant blood glucose patterns.



Jentaducto®: CHMP recommend approval

The Committee for Medicinal Products for Human Use (CHMP) has recommended European approval of Jentaducto® for use with diet and exercise to improve glycaemic control in patients with type 2 diabetes.

Combining the dipeptidyl peptidase-4 inhibitor linagliptin and metformin in a single tablet, Jentaducto® could provide an alternative treatment option for patients who have not achieved adequate control of their blood glucose with metformin alone or in combination with linagliptin.

Fixed combinations may increase patient adherence to treatment and “are to be welcomed” says Tony Barnett, Professor of Medicine, University of Birmingham, UK.

Novo Nordisk FlexTouch®

The FlexTouch® disposable insulin pen has been ranked better than the InnoLet® doser with respect to injection and handling procedure in patients with poor eyesight or manual dexterity.

The study ($n=90$) by the Institute for Clinical Research and Development (IKFE; Mainz, Germany) reported 92% of patients recommended FlexTouch® over InnoLet®.

Gwen Hall, Diabetes Specialist Nurse and Vice Chair of the Primary Care Diabetes Society, said: “This study confirms that this ... innovative device gives [people] more choice to effectively manage their diabetes.”

The study findings were presented at the 2012 Diabetes UK Professional Conference.

Media



Digest

MEDIA LITE

Maple syrup: Worth tapping into

The “super food” list is ever growing and new research could add to it the Canadian classic, maple syrup. It may not appear the obvious candidate, but researchers at the University of Rhode Island have identified a variety of polyphenols, potentially anti-diabetic compounds, in the syrup, highlighting a potential new way of managing type 2 diabetes.

Sounds like this could be something worth tapping into!

The Daily Mail
2 April 2012

Low testosterone and diabetes risk

Low testosterone levels in men are linked to an increase in risk of developing type 2 diabetes, study results suggest.

Researchers at Edinburgh University investigated impaired testosterone in mice, finding those with low fat tissue testosterone levels had raised RBP4 protein levels and were more likely to be insulin resistant, regardless of body weight.

As men age, testosterone levels fall and the study findings may help explain why older men are more at risk of developing diabetes, and lead to treatments targeting RBP4.

BBC News
3 May 2012

Caesarean section doubles obesity risk

Caesarean section doubles the risk of obesity compared with normal delivery, according to new research.

Researchers from Boston Children's Hospital, Massachusetts measured and weighed children at birth and 3 years of age. Results indicated a relationship between the route of delivery and the child's body mass and skin thickness.

The Royal College of Obstetricians and Gynaecologists commented: “This is an interesting study but small and needs to be replicated in a bigger sample.”

BBC News
24 May 2012